Abstract Background The diabetic heart exhibits a high sensitivity to ischaemia/reperfusion (I/R) injury. Diabetes mellitus (DM) can affect the efficacy of cardioprotective interventions and reduce the therapeutic potential of existing treatment options. This study aimed to investigate the feasibility of shifting from monotherapy to combination therapy in diabetic myocardial I/R injury. Methods 6–8 week rats were randomized into 10 groups: sham, I/R, ischaemia postconditioning (I-Post), nicorandil (Nic), combination therapy (I-Post + Nic), DM sham, DM I/R, DM I-Post, DM Nic and DM I-Post + Nic. The extent of myocardial injury was clarified by measuring CK-MB and NO levels in plasma, ROS content in myocardial tissues, and TTC/Evans Blue stai...
Background- Coronary heart disease is the leading cause of death in the Western world and targeting ...
Background: Myocardial ischaemia and reperfusion (I/R) injury, a major global public health problem...
Experiments were designed to assess whether (1) nicorandil given before global low-flow ischemia or ...
Objective. The present study was designed to determine whether dexmedetomidine (DEX) exerts cardiopr...
Erdem, Ayhan/0000-0001-7761-1078; Arslan, Mustafa/0000-0003-4882-5063;WOS: 000421768300004Objective:...
Objective(s): Chronic diabetes impedes cardioprotection in reperfusion injury and hence protecting t...
Diabetic patients are at increased risk of developing coronary artery disease and experience worse c...
Conference Theme: Transforming the Future through ScienceSession: Pharmacology and Experimental Ther...
The cardioprotective effects of nicorandil (NIC) in isolated blood perfused rat hearts using support...
Abstract Background: Remote ischemic preconditioning (IPreC) could provide tissue-protective effect...
The cardioprotective effects of nicorandil (NIC) in isolated blood perfused rat hearts using support...
Aims: The diabetic heart is resistant to the myocardial infarct-limiting effects of ischemic precond...
Abstract Purpose Patients with diabetes are vulnerable to myocardial I/R (ischaemia/reperfusion) i...
Abstract In spite of the current optimal therapy, the mortality of patients with ischemic heart dise...
OBJECTIVES: To study the protective mechanism of nicorandil on myocardial ischemia-reperfusion injur...
Background- Coronary heart disease is the leading cause of death in the Western world and targeting ...
Background: Myocardial ischaemia and reperfusion (I/R) injury, a major global public health problem...
Experiments were designed to assess whether (1) nicorandil given before global low-flow ischemia or ...
Objective. The present study was designed to determine whether dexmedetomidine (DEX) exerts cardiopr...
Erdem, Ayhan/0000-0001-7761-1078; Arslan, Mustafa/0000-0003-4882-5063;WOS: 000421768300004Objective:...
Objective(s): Chronic diabetes impedes cardioprotection in reperfusion injury and hence protecting t...
Diabetic patients are at increased risk of developing coronary artery disease and experience worse c...
Conference Theme: Transforming the Future through ScienceSession: Pharmacology and Experimental Ther...
The cardioprotective effects of nicorandil (NIC) in isolated blood perfused rat hearts using support...
Abstract Background: Remote ischemic preconditioning (IPreC) could provide tissue-protective effect...
The cardioprotective effects of nicorandil (NIC) in isolated blood perfused rat hearts using support...
Aims: The diabetic heart is resistant to the myocardial infarct-limiting effects of ischemic precond...
Abstract Purpose Patients with diabetes are vulnerable to myocardial I/R (ischaemia/reperfusion) i...
Abstract In spite of the current optimal therapy, the mortality of patients with ischemic heart dise...
OBJECTIVES: To study the protective mechanism of nicorandil on myocardial ischemia-reperfusion injur...
Background- Coronary heart disease is the leading cause of death in the Western world and targeting ...
Background: Myocardial ischaemia and reperfusion (I/R) injury, a major global public health problem...
Experiments were designed to assess whether (1) nicorandil given before global low-flow ischemia or ...